ArticleBiomarkers in medicine2025
Prognostic value of inflammatory-nutritional indexes and HALP score in advanced stage NSCLC treated with first-line TKI.
Article in Biomarkers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Association between the systemic inflammation response index and prognosis in lung cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimIn metastatic Non-small cell lung cancer (NSCLC) with driver mutations, resistance mechanisms may limit treatment benefit, and their detection is expensive. The aim of this retrospective study was to investigate the usability of inflammatory-nutritional indices and hemoglobin, albumin, lymphocyte and platelet (HALP) scores for predicting survival in patients with metastatic NSCLCs with driver mutations undergoing first-line treatment with tyrosine kinase inhibitors (TKIs). PATIENTS &
methodsNinety-two patients using TKIs for metastatic disease with driver mutations were followed up in our center from December 2018 to May 2024. We retrospectively investigated the effects on progression-free survival (PFS) and overall survival (OS) by calculating inflammatory-nutritional indices and HALP scores using pre-treatment laboratory values.
resultsHigher plate-let-to-lymphocyte ratios (PLRs) were associated with shorter PFS, whereas a higher prognostic nutritional index (PNI) predicted longer PFS. Similarly, high HALP and PNI scores were significantly associated with longer OS, while lower platelet-to-lymphocyte ratio (PLR), systemic immune inflammatory index (SII) and systemic inflammation response index (SIRI) were linked to improved OS. Multivariate analysis identified only SII as an independent OS prognostic factor (OR = 7.182,
conclusionsHALP score, PLR, SII, PNI and SIRI may serve as potential prognostic biomarkers in NSCLC patients with driver mutations treated with first-line TKIs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.